Saudi disclosure set at SR 50 as Egypt holds WHO Level 3
Transfers of value to healthcare practitioners are disclosed through a Saudi regulator service, while Egypt's authority retained its World Health Organization maturity rating.
Saudi disclosure of financial and in-kind support given to healthcare practitioners runs through an electronic service operated by the Saudi Food and Drug Authority. Hibridge, a Cairo healthcare consulting firm, states on its own site that it serves pharmaceutical companies across Egypt, the Gulf and the Levant.
The Saudi disclosure obligation#
The Saudi Food and Drug Authority operates a disclosure and transparency electronic service for financial or in-kind support that medical and nutrition companies give to healthcare practitioners and institutions. Its page for the service sets out annual disclosure by file for each recipient and allows practitioners to disclose for themselves. MediSpend's summary of the obligation lists consulting, speaker and training fees, sponsorship of attendance at educational events, symposium and conference sponsorship, research and educational grants, hospitality, gifts and samples among the reportable categories, and covers transfers inside Saudi Arabia and abroad.
Where the thresholds come from#
MediSpend puts the thresholds at meals and hospitality above SR 50, amounts paid to practitioners or institutions above SR 50 per payment, and an annual aggregate per recipient above SR 500, and notes that the supervising authority may update them. The summary states that the obligation covers transfers made inside Saudi Arabia and transfers made abroad, and lists payments made through third parties among the reportable items.
What Egypt's authority published#
The Egyptian Drug Authority put the 2025 Egyptian pharmaceutical market at EGP 422 billion, about US$8.5 billion, and reported that local factories make about 91 percent of the medicines consumed in the country. The Egyptian Gazette reported on 19 August 2026 that the authority retained World Health Organization Maturity Level 3 status for the regulation of medicines and vaccines following a follow-up benchmarking visit, that it holds that rating for both medicines and vaccines, and that it is working towards Level 4 within its current development cycle.
What the Cairo firm's site states#
Hibridge gives 2014 as its founding year and Cairo as its base, and states that it serves pharmaceutical companies across Egypt, the Gulf and the Levant. Its compliance page states that the standards it reviews against are Egyptian requirements, market codes for the Gulf and global corporate policy, and that an in-house team reviews transfer-of-value treatment before work reaches a client. It states that fair market value, contracting and spend capture are documented as an activity happens. Related company announcements sit with the Corridors Desk.
Sources6 sources across 5 domains
- sfda.gov.saSaudi Food and Drug AuthorityThe Saudi Food and Drug Authority operates a disclosure and transparency electronic service for financial or in-kind support given by medical and nutrition companies to healthcare practitioners and institutions, with annual disclosure by file per recipient and self-disclosure by practitioners, and states no thresholds or category list on that page
- medispend.comMediSpendReportable categories for Saudi transfers of value including consulting, speaker and training fees, sponsorship of attendance, conference sponsorship, grants, hospitality, gifts and samples; thresholds of SR 50 for meals and hospitality, SR 50 per payment and SR 500 annual aggregate per recipient, which the supervising authority may update; the obligation covers transfers inside Saudi Arabia and abroad and includes payments made through third parties
- zawya.comZawyaReporting the Egyptian Drug Authority statement of 15 June 2026. Egypt pharmaceutical market EGP 422 billion, about US$8.5 billion, in 2025, with about 91 percent of consumed medicines produced locally
- egyptian-gazette.comEgyptian GazettePublished 19 August 2026. Egyptian Drug Authority maintained WHO Maturity Level 3 status for medicines and vaccines after a follow-up benchmarking visit and is targeting Level 4 within its current development cycle
- hibridge.egHibridgeHibridge founded 2014 in Cairo, states it serves pharmaceutical companies across Egypt, the GCC and the Levant
- hibridge.egHibridgeHibridge states it reviews against Egyptian requirements, GCC market codes and global corporate policy, that an in-house team reviews transfer-of-value treatment before work reaches the client, and that fair market value, contracting and spend capture are documented as the activity happens
Each source above carries the claim it supports. Links open the publisher's own page; their text is not reproduced here beyond what the claim requires, and their rights remain theirs.
MENA Trade is published by Arabian Media Network. Pieces are produced by the Corridors Desk with AI-assisted synthesis of the cited sources and automated verification against the network's editorial policy. Every piece carries a desk rather than a reporter. Corrections are recorded on the piece and on the corrections page.